Gene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis

Epilepsy Clinical Trial

Official title:

Gene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04917939
• Other study ID #: 2021-0291
• Status: Active, not recruiting
• Start date: April 19, 2021
• Est. completion date: December 2022

Study information

• Verified date: June 2021
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Epilepsy is a common neurological disease, manifested in the sudden abnormal discharge of neurons leading to short-term brain dysfunction, has become the neurology after headache the second most common disease. In China, the prevalence of epilepsy is about 4.7-8.5 per 1,000, and more than 400,000 new cases of epilepsy are developed each year. Of these, 30% of patients were treated with ineffective medication, developing into a drug-incurable epilepsy that required surgery and other treatments. The most common type of epilepsy is temporal lobe epilepsy, while the common complication in temporal lobe epilepsy is hippocampal sclerosis, which often requires surgical removal. The incidence of inner temporal lobe epilepsy associated with hippocampal sclerosis is increasing, but its exact cause and specific pathogenesis are still unclear, so clarifying its pathogenesis will contribute to the understanding of temporal lobe epilepsy and the improvement of surgical procedures. This study is intended to get single-cell transcriptome as well as spatial transcriptome data of temporal lobe and hippocampus samples. By studying gene expression change associated with epilepsy and hippocampus sclerosis, we intended to find possible prognostic-related molecules and to deepen understanding of pathological changes in epilepsy at the molecular level.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: December 2022
• Est. primary completion date: September 2022
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients confirmed in our hospital as having temporal lobe epilepsy and intending surgery to remove temporal lobe and hippocampal tissue;

• Volunteer to participate in this clinical trial, comply with the requirements of this clinical trial and sign an informed consent form.

Exclusion Criteria:

• Chronic diseases of the central nervous system other than temporal lobe epilepsy;

• Other patients that are not suitable for this clinical trial determined by the researchers;

Related Conditions & MeSH terms

• Epilepsy
• Epilepsy, Temporal Lobe
• Sclerosis

Intervention

Other:
• RNA sequencing
Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.

Locations

Country	Name	City	State
China	2ndAffiliated Hospital, School of Medicine, Zhejiang University, China	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RNA sequencing data	Single-cell sequencing and spatial transcription sequencing data of samples.	up to 24 weeks